These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22269152)

  • 1. Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia.
    Lee SH; Cho KI; Kim JY; Ahn YK; Rha SW; Kim YJ; Choi YS; Choi SW; Jeon DW; Min PK; Choi DJ; Baek SH; Kim KS; Byun YS; Jang Y
    Atherosclerosis; 2012 Mar; 221(1):169-75. PubMed ID: 22269152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
    Polenova NV; Vaulin NA; Masenko VP; Iavelov IS; Gratsianskiĭ NA
    Kardiologiia; 2009; 49(2):9-14. PubMed ID: 19254210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
    Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
    Jones PH; Davidson MH; Kashyap ML; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
    Atherosclerosis; 2009 May; 204(1):208-15. PubMed ID: 18996523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate.
    Ireland JH; Eggert CH; Arendt CJ; Williams AW
    Ann Intern Med; 2005 Jun; 142(11):949-50. PubMed ID: 15941707
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
    Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
    Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
    Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
    Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?
    Milionis HJ; Gazi IF; Filippatos TD; Tzovaras V; Chasiotis G; Goudevenos J; Seferiadis K; Elisaf MS
    Angiology; 2005; 56(5):585-92. PubMed ID: 16193198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Tselepis AD; Elisaf MS
    Lipids; 2011 Jun; 46(6):521-8. PubMed ID: 21327725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study.
    Laks T; Keba E; Leiner M; Merilind E; Petersen M; Reinmets S; Väli S; Sööt T; Otter K
    Vasc Health Risk Manag; 2008; 4(6):1407-16. PubMed ID: 19337553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hyperlipidaemia with fenofibrate and related fibrates.
    Filippatos T; Milionis HJ
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1599-614. PubMed ID: 18808320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.
    Pepine CJ; Jacobson TA; Carlson DM; Kelly MT; Setze CM; Gold A; Stolzenbach JC; Williams LA
    Clin Cardiol; 2010 Oct; 33(10):609-619. PubMed ID: 20960535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of atherosclerosis in patients living with HIV.
    De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
    Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
    McKenney JM
    Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.